Navigation Links
New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
Date:11/1/2008

c hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation).

PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and is administered orally two times a day as a split dose. Roche has backed PEGASYS with the most extensive clinical research program ever undertaken in hepatitis C, with major studies initiated to advance treatment for hepatitis C patients with unmet needs, including patients co-infected with HIV and HCV, African Americans, patients with cirrhosis, and patients who have failed to respond to previous therapy.

IMPORTANT SAFETY INFORMATION

PEGASYS, alone or in combination with COPEGUS, is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A).

Alpha interferons, including PEGASYS(R) (Peginterferon alfa-2a), may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping PEGASYS therapy (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

Use with Ribavirin. Ribavirin, including COPEGUS(R), may cause birth defects and/or death of the fetus. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin causes hemolytic anemia. The anemia associated with ribavirin therapy may resu
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New International Study Shows Women With Symptomatic Fibroids Delaying Treatment Despite Substantial Burden on Quality of Life
2. Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD
3. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
4. Grapes May Aid a Bunch of Heart Risk Factors, U-M Animal Study Finds
5. NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation
6. Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
7. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults
10. New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
11. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... WASHINGTON , March 4, 2015  Vanda ... today announced top-line results of the Phase II ... and efficacy of tradipitant as a monotherapy in ... atopic dermatitis. Despite a highly significant and clinically ... from baseline, p<0.0001) as measured on a 100mm ...
(Date:3/4/2015)... 2015 Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... regenerative medicine, today announced that Pedro Lichtinger , ... Bell ® of the New York Stock Exchange ... as an NYSE MKT listed company on October 8, ... a trusted partner to Asterias Biotherapeutics, and we are ...
(Date:3/4/2015)... InfuSystem Holdings, Inc. (NYSE MKT: INFU), a ... for the U.S. healthcare industry, today announced that it ... results on Monday, March 9, 2015 after the market ... conference call for investors on Monday, March 9, 2015 ... and full year 2014 performance and results.  To participate ...
Breaking Medicine Technology:Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 2Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 3
... Market to Demonstrate Test,s Potential for ... Rapid ... DIAG) and Applied Biosystems Inc. (NYSE: ABI ) today,announced the launch ... searches for a unique gene expression signature,identified by DiaGenic using a custom ...
... Have Other Important Benefits, Says CRN-, WASHINGTON, ... Study II, to be released at the American ... the November 12,issue of the Journal of the ... vitamin E and C supplementation on cardiovascular,events in ...
Cached Medicine Technology:Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test 2Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test 3Physicians' Health Study II Finds No Magic Bullet for Preventing Cardiovascular Disease 2Physicians' Health Study II Finds No Magic Bullet for Preventing Cardiovascular Disease 3Physicians' Health Study II Finds No Magic Bullet for Preventing Cardiovascular Disease 4
(Date:3/4/2015)... With the growing influence of movies, television, video games and ... adults, combined with the increasingly frantic lifestyle of modern parents, ... up with what kids are into these days. It seems ... daily basis. , The same is also true for drugs ... to discreetly talk about them, are constantly changing. These tips ...
(Date:3/4/2015)... More than a year after announcing ... with low testosterone treatments ( http://www.testosteronelawsuithub.com/ ), the U.S. ... now require manufacturers to warn patients that this class ... and strokes. In a Drug Safety Communication ... it was requiring testosterone manufacturers to update the drugs’ ...
(Date:3/4/2015)... 04, 2015 Vancouver chiropractic clinic, ... two awards in the prestigious Vancouver Courier “Stars ... 27, 2015. The company secured third place in ... the “Best Registered Massage Therapist” category. , ... in Canada, The Vancouver Courier is a semiweekly ...
(Date:3/4/2015)... York, NY (PRWEB) March 04, 2015 ... the centerfold of The San Francisco Chronicle with a ... of 500,000 readers. Its digital component is distributed nationally ... network of top news sites and partner outlets. To ... here. , Milorganite is composed of heat-dried ...
(Date:3/4/2015)... 2015 State officials have awarded $82,500 ... of Public Health at Georgia State University, to support ... by Georgia’s Division of Family and Children Services (DFCS) ... Call Center. , The 1-800-CHILDREN Helpline is a ... and referral services that promote the wellbeing of children ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4Health News:Backs in Action Receives Two Awards in The Vancouver Courier Readers’ Choice Awards 2015 2Health News:State Funds Child Abuse Helpline Housed At Georgia State 2
... , , , , , , ... Medical,International Limited (NYSE: MR ), a leading developer, ... at its annual general meeting of shareholders held in Hong ... the meeting, Mindray Medical International,s shareholders approved the,re-election of directors ...
... causes more pain than vodka, study finds , FRIDAY, Dec. ... a common indulgence -- and nasty hangovers a common consequence. ... lighter-colored beverages, they might feel a little better the next ... contain more toxic properties that provoke more painful hangovers than ...
... , , , NEWPORT BEACH, Calif., Dec. 18 ... announced today that it has given notice that it is ... Cumulative Convertible Preferred Stock ("Series B Preferred Stock") (NHP-PB - ... price per share of $103.875 plus an amount equal to ...
... thoughts may help explain interpersonal problems , FRIDAY, Dec. ... are less active than expected when they,re engaged in ... difficulties, say British researchers. , Using functional MRI, they ... whom had autism, while they were asked questions about ...
... CentraCare president is new chair , ST. PAUL, Minn., Dec. ... systems, recently elected or re-elected the following members to its board for ... Chair - Terence Pladson, M.D., president, CentraCare Health System, ... CEO, Queen of Peace Hospital, New Prague, Secretary/treasurer - ...
... , , HOUSTON, Dec. 18 ... largest provider of deathcare products and services in North America, ... has extended the expiry time of its offer (the "Offer") ... and outstanding common shares in the capital of Keystone North ...
Cached Medicine News:Health News:Mindray Medical International Limited Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting 2Health News:For a Lighter Hangover, Avoid Darker Drinks 2Health News:For a Lighter Hangover, Avoid Darker Drinks 3Health News:For a Lighter Hangover, Avoid Darker Drinks 4Health News:Nationwide Health Properties, Inc. Announces the Redemption of All Outstanding Shares of 7.75% Series B Cumulative Convertible Preferred Stock 2Health News:Brain Imaging Sheds Light on Social Woes Related to Autism 2Health News:Minnesota Hospital Association Elects, Re-Elects Members to Board 2Health News:Service Corporation International Extends Offer for Keystone North America Inc. 2Health News:Service Corporation International Extends Offer for Keystone North America Inc. 3
McIntyre-Binkhorst Cannula have a smooth blunt tip end opening....
Army navy retractor set....
Sharp. 4 mm wide. Hand-Held...
Adsons bayonet forceps....
Medicine Products: